AMP579 (1) is a novel adenosine analogue with high affinity for both the A1 (Ki∼ 5 nM) and A2a (Ki∼ 56 nM) receptor subtypes and has recently been demonstrated in a clinically relevant manner to have cardioprotective effects in various animal models of myocardial infarction. 1, 2 It is currently under development for potential use in cardiovascular therapeutics. 3 Structurally, 1 is distinguished from adenosine by: 5′-N-ethylcarboxamide ...
